)
Lonza Group (LONN) investor relations material
Lonza Group Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategy and execution
Strategy centers on a pure-play, multi-modality CDMO model, investment in innovative modalities, resilient global infrastructure, disciplined capital allocation and profitable above-market growth.
A new operating model launched on April 1, 2025, organizing operations into Advanced Synthesis, Integrated Biologics and Specialized Modalities; management linked it to stronger execution and financial performance.
The CHI sale, signed in March 2026, is valued at CHF 1.6bn-CHF 1.7bn and expected to close by year-end 2026; portfolio exits establish a pure-play CDMO focus.
Net Promoter Score doubled among big pharma customers and improved 50% among small biotechs; 70% of new molecules are based on integrated services.
Management said it met its December 2024 commitments and met or raised its 2025 and 2026 outlooks during those years.
Market and growth model
The underlying market has grown 6%-7% over decades; selected faster-growing segments add 1%-2% and pharmaceutical outsourcing to CDMOs adds another 1%-2%, supporting an 8%-10% addressable-market growth estimate.
The differentiated operating model is expected to add 2%-3% growth above the market; average long-term top-line ambition is 10%-13%.
The organic growth model targets low-teens average organic CER sales growth, expanding margins and midterm core EBITDA margin in the high 30s; growth investment is mid-to-high teens as a percentage of sales.
Since 2024, profitability increased by 4 percentage points over two years; management said growth accelerated to a 16%-17% CAGR, with ROIC and cash generation also rising.
Long-term ROIC ambition is 2-3x WACC; management described a progressive trajectory as the growth model rolls forward with increasing profitability.
Capacity and differentiated services
Active CapEx portfolio comprises 25 global projects worth CHF 8bn, with 90% directed to commercial mixed assets; expected peak ROIC is 30%-40%.
Services span eight modalities, product life cycles from preclinical to commercial, and scales from lab to large-scale manufacturing, addressing clients’ manufacturability needs.
The GS cell-line system has supported more than 100 drugs brought to market; the DNA-to-IND timeline is now six months.
ADC capacity investment continues in Visp, including a recently announced payload-linker project; management said capacity is available while additions are made to support growth.
- Five U.S. CDMO sites add specialized capacity, targeting profitable growth by the mid-2030s.LONN
M&A announcement - Sales rose 10.9% CER; earnings faced CHF 489m in charges and 2024 guidance is flat.LONN
H2 2023 - 10%-13% growth ambitions pair with high-30s margins and disciplined CDMO investment.LONN
CMD 2026 - Robust segment growth and disciplined strategy drive sustainable margins and cash flow.LONN
Morgan Stanley 24th Annual Global Healthcare Conference - H1 2026 sales rose 16% at CER, CORE EBITDA margin reached 34.8%, and outlook was upgraded.LONN
H1 2026 - CHI divestment finalizes pure-play CDMO focus, unlocking CHF 3B+ for growth and buybacks.LONN
Investor update (Q&A) - 2025 CDMO sales growth to approach 20%, with core EBITDA margin nearing 30%.LONN
Investor Update - H1 2024 delivered robust sales and EBITDA, with Vacaville set to double mammalian capacity.LONN
H1 2024 - Flat sales, strong CDMO, US expansion, and CHI exit drive strategic transformation.LONN
H2 2024
)
)
)
)
)
)
)
)